1. Introduction {#sec1}
===============

A decrease in functional beta-cell mass is a key feature of type 2 diabetes [@bib1], [@bib2]. Increasing evidence indicates that alterations in the balance between anti- and pro-inflammatory cytokines may play a role in the pathogenesis not only of type 1 but also type 2 diabetes in humans and may possibly underlie decreased beta-cell function/mass in the latter condition. Type 2 diabetes is thus associated with chronic low-grade inflammation and immune cell infiltration in islets, though this occurs at a lesser degree than in islets from type 1 diabetic patients [@bib3]. Additionally, it is known that islet endocrine cells are able to produce certain cytokines, both pro- and anti-inflammatory [@bib4], [@bib5]. The detrimental effects of pro-inflammatory pathways triggered by T-helper-1 (Th1) cytokines (e.g. IL-1β, TNFα, IFNγ) in islets have been widely studied and are implicated in beta-cell failure [@bib6]. By contrast, the effects of Th2 cytokines (e.g. IL-4 and IL-13) on islets and more specifically on beta-cells have been investigated only in few studies [@bib7] and mainly on transformed rodent beta-cell lines.

IL-13 is secreted by activated Th2 cells and classified as an anti-inflammatory cytokine due to its ability to suppress the secretion of several macrophage and monocyte-derived inflammatory cytokines. IL-13 mediates its effects by interacting with a complex receptor system comprised of IL-4Rα and IL-13Rα1 with downstream activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling cascade and the PI3kinase pathway through recruitment of insulin receptor substrate members [@bib8], [@bib9].

IL-13 plays a key role in the regulation of hepatic glucose production in mice [@bib10]. Moreover, IL-13 plasma levels are reduced in type 2 diabetic patients compared to healthy individuals and IL-13 exerts an autocrine effect on glucose metabolism in skeletal muscle [@bib11]. Most recently, it has been found that IL-13 is induced in adipose tissue of obese humans and high-fat fed mice, and that the source of such IL-13 is primarily adipocytes [@bib6].

IL-13 is able to impact positively on transformed rodent beta-cell lines and on intact rat islets [@bib12], [@bib13], [@bib14]. Indeed, IL-13 increases Rinm5F cell viability and improves that of INS1E cells following serum starvation or when challenged with palmitate. IL-13 has also been found to counteract the suppression of rat islet glucose oxidation induced by IL-1β [@bib14].

Against this background, we wanted to explore the impact of IL-13 on primary human or rat beta-cell function and survival and the mechanism underlying these putative effects. Our study shows for the first time that IL-13 protects primary beta-cells against IL-1β and mixed cytokine induced cell death without affecting proliferation or insulin secretion. These effects are mediated through the IRS2/Akt signaling cascade, and IL-13 further regulates the expression of a small number of specific genes involved in the beta-cell response to stress, albeit independently of NFκB.

2. Materials and methods {#sec2}
========================

2.1. Human islets, sorted beta-cells {#sec2.1}
------------------------------------

Human islets were kindly provided by the Cell Isolation and Transplant Centre of the University of Geneva (JDRF award 31-2008-413, ECIT Islet for Basic Research Program). Human islets were dispersed by Acutase (PAA Laboratories, Austria) and beta-cells were sorted by FACS after labeling with Newport Green using a FACSVantage (Becton Dickinson, Franklin Lakes, NJ, USA) as previously described [@bib15].

For functional analysis and immunostaining, human islets, non sorted single cells or sorted beta-cells were cultured in CMRL-1066 medium containing 5 mM glucose, 100 units/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamax, 250 μg/ml gentamycin, 10 mM Hepes and 10% fetal calf serum (FCS) (Invitrogen, Switzerland) on plastic dishes coated with extracellular matrix secreted by 804G rat bladder cancer cells (804G ECM), as described elsewhere [@bib15] and were left in islet medium for 24 h to adhere and spread before initiation of the experiments.

2.2. Rat islets, sorted beta-cells {#sec2.2}
----------------------------------

Islets were isolated by collagenase digestion of pancreas from adult male Wistar rats. Beta-cells were separated from non beta-cells by autofluorescence using a FACSVantage as described previously [@bib15]. Islet dispersed cells, sorted beta-cells and sorted non beta-cells were cultured in DMEM medium containing 11 mM glucose, 0.05 mg/ml gentamicin, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% FCS (Invitrogen, Switzerland). Cells were cultured on 804G ECM-coated plates as described elsewhere [@bib15] and were left for 24 h to adhere and spread before initiation of the experiments.

2.3. Western blotting {#sec2.3}
---------------------

Beta-cell protein lysate was separated by SDS-PAGE, transferred to Immobilon-P membranes (Merck Millipore, Germany) and probed with anti-NFkB and anti-phospho-NFkB (p65) (Santa Cruz Biotechnology, USA), anti-IRS2, Akt1, Akt2, anti-phospho Akt (Serine 473) (Cell Signaling Technology, USA) and anti-actin (Merck Millipore, Germany).

2.4. RNA extraction, library preparation, sequencing, mapping and expression quantification {#sec2.4}
-------------------------------------------------------------------------------------------

Total RNA was prepared according to the manufacturer\'s instructions (ReliaPrep RNA Cell Miniprep System, Promega, USA). PolyA + RNA library construction and sequencing were performed as described elsewhere [@bib16]. The 49 bp paired-ends reads were mapped with gemtools v1.7.1 [@bib17], [@bib18] onto the Rnor_5.0 genome and onto the Rnor_5.0.73 gene annotation. A maximum of 5 mismatches was allowed for the alignment and reads having a mapping quality score below 150 were filtered out.

The differential expression analysis was performed with the DESeq2 software [@bib19] by taking into account the batch and the GC content of each sample.

2.5. Insulin secretion {#sec2.5}
----------------------

For acute insulin release in response to glucose, islets and beta-cells were preincubated for 2 h (2.8 mM glucose) and incubated in Krebs--Ringer bicarbonate Hepes buffer, 0.5% BSA (KRB) containing 2.8 mM glucose for 1 h followed by 1 h incubation in KRB containing 16.7 mM glucose. Total insulin was extracted with 0.18 M HCl in 70% ethanol for determination of insulin content. Insulin was measured by radioimmunoassay.

2.6. Immunofluorescence, cell proliferation and cell death {#sec2.6}
----------------------------------------------------------

Dispersed islet cells or sorted beta-cells were treated for 48 h with IL-13 (Preprotech, USA) in the continued presence of BrdU. The incorporated BrdU was detected with the BrdU-detection kit (Roche, Switzerland) and beta-cells were co-stained with anti-insulin antibody (Dako, Denmark). The free 3-OH strand breaks were detected by the terminal deoxynucleotidyl-transferase-mediated deoxyuridine 5-triphosphate nick-end labeling (TUNEL) technique according to the manufacturer\'s instructions (In situ cell death detection kit, Roche, Switzerland). The cells were co-stained with either an anti-insulin or an anti-glucagon antibody (Dako, Denmark). NFκB was localized by an anti-NFκB p65 antibody (Santa Cruz Biotechnology, USA), and beta-cells appeared co-stained with an anti-insulin antibody. The numbers of TUNEL-positive or BrdU-positive cells, or cells with nuclear localization of NFκB were determined by blinded counting with a fluorescent microscope. For each condition in each individual experiment, over 1000 cells were analyzed.

2.7. Immunofluorescence and confocal microscopy {#sec2.7}
-----------------------------------------------

Primary antibodies were as follows: rabbit anti-phospho (Y397) FAK pAb and mouse anti-paxillin monoclonal (BD Transduction Laboratories (San Jose, CA, USA)); secondary antibodies were as follows: donkey anti-rabbit Alexa Fluor 488 and donkey anti-mouse Alexa Fluor 555 (Invitrogen, Switzerland). To visualize F-actin, Alexa Fluor 647-phalloidin was used (Invitrogen, Switzerland). Immunofluorescence and confocal microscopy on sorted beta-cells were performed as previously described [@bib20]. The basal membranes of cells were observed under a Zeiss LSM510 Meta confocal microscope using a 63x oil immersion lens. Images were acquired and processed using the LSM510 software (Carl Zeiss AG, Germany).

2.8. Statistical analyses {#sec2.8}
-------------------------

Data are expressed as means ± SEM, with the number of individual experiments presented in the figure legends. All data were tested for normality and analyzed with PRISM (GraphPad, USA). Differences were evaluated using Student\'s t test and ANOVA with Bonferroni post hoc test for multiple comparison analysis. Significance was set as p \< 0.05.

3. Results {#sec3}
==========

3.1. IL-13 decreases beta-cell apoptosis without affecting insulin secretion and proliferation {#sec3.1}
----------------------------------------------------------------------------------------------

We first analyzed the impact of IL-13 on the function (insulin content and secretion) of human islets, rat dispersed islet cells and sorted rat beta-cells. Neither insulin secretion ([Figure 1A,B and C](#fig1){ref-type="fig"}) nor cellular insulin content (data not shown) was significantly influenced by IL-13 in any cell preparation. We also investigated the impact of IL-13 on rat beta-cell proliferation (note that this was not possible using adult human beta-cells since they do not replicate to any meaningful extent in vitro [@bib21]). Replication was assessed by BrdU incorporation over 48 h. As for insulin secretion, IL-13 did not affect rat beta-cell proliferation ([Figure 1](#fig1){ref-type="fig"}D).

By contrast, IL-13 significantly decreased death of human beta-cells under standard culture conditions ("basal" cell death) independently of the presence of other islet cell types (human dispersed islet cells ([Figure 1](#fig1){ref-type="fig"}E) versus sorted beta-cells ([Figure 1](#fig1){ref-type="fig"}F). Using rat primary islet cells, IL-13 was able to decrease basal cell death of beta-cells within a population of dispersed (non-sorted) rat islets ([Figure 1](#fig1){ref-type="fig"}G). It was not possible to observe any significant effect of IL-13 on death of sorted rat beta-cells under basal culture conditions due to the very low level of dying cells in the control situation (0.06 ± 0.02% TUNEL-positive cells, [Figure 1](#fig1){ref-type="fig"}H).

3.2. IL-13 induces Akt phosphorylation and upregulates IRS2 {#sec3.2}
-----------------------------------------------------------

To investigate the putative pathway(s) involved in IL-13 decreased beta-cell apoptosis, we measured Akt phosphorylation, a central player in beta-cell survival [@bib22], in sorted primary rat beta-cells since human material is not readily available and to avoid noise from non beta-cells. Already after 60 min treatment, IL-13 was able to increase Akt serine 473 phosphorylation ([Figure 2](#fig2){ref-type="fig"}A). This effect tended to be maintained after 48 h IL-13 treatment ([Figure 2](#fig2){ref-type="fig"}B), albeit without achieving statistical significance, and there was no change in protein expression of either Akt1 or Akt2 isoforms ([Figure 2](#fig2){ref-type="fig"}C, D). Interestingly, IRS2 total protein expression was increased after 48 h treatment with IL-13 ([Figure 2](#fig2){ref-type="fig"}E).

It has been previously demonstrated that actin and focal adhesion (FA) remodeling are essential for insulin secretion. Indeed, glucose stimulation led to bundling of actin filaments, with FAK and PAX activation by phosphorylation and their localization in filopodial extensions called FAs in beta-cells [@bib23]. However, in embryonic fibroblasts, FAK has been also demonstrated to be involved in cell survival via NF-κB and ERK signaling pathways [@bib24]. We have treated rat primary beta-cells with IL-13 for 48 h and observed the actin and FA remodeling by confocal microscopy ([Figure 2](#fig2){ref-type="fig"}F). IL-13 induced an important remodeling of actin in thick filament and increase the number of protrusions at basal cell membrane containing FAK phosphorylated form and paxillin. Moreover, western blot analyses of paxillin protein expression revealed an increase level of this protein upon IL-13 treatment (1.24 ± 0.07 (AU) fold over control). IL-13-induced adhesion could be involved in beta-cell survival observed in [Figure 1](#fig1){ref-type="fig"}.

3.3. IL-13 increases the expression of 4 beta-cell genes {#sec3.3}
--------------------------------------------------------

The transcriptome analysis of rat beta-cells treated for 48 h with IL-13 revealed only 5 genes that were differentially expressed compared to control cells. Among these 5 genes, one was a pseudogene. Interestingly, IL-13 upregulated Cish and Cd83 gene expression ([Figure 3](#fig3){ref-type="fig"}A,B), two genes involved in cytokine response and antigen presentation. Cish is part of a classical negative feedback system that regulates cytokine signal transduction [@bib25]. Cd83 is involved in antigen presentation and single-nucleotide polymorphisms (SNPs) in this gene have been shown to be associated with type 1 diabetes [@bib25]. The two other genes upregulated by IL-13, Galnt14 and St6galnac3 ([Figure 3](#fig3){ref-type="fig"}C,D), are transferases that have so far never been investigated in beta-cells or in the context of diabetes.

3.4. IL-13 protects beta-cells from IL-1β induced cell death but not from the associated impairment of glucose-stimulated insulin secretion {#sec3.4}
-------------------------------------------------------------------------------------------------------------------------------------------

As mentioned earlier, in our experimental approach (cells coated on ECM) basal level of apoptosis in sorted rat beta-cells is almost non-detectable (\<0.1% TUNEL-positive cells). Therefore, sorted rat beta-cells were exposed to IL-1β alone or in combination with IFNγ and TNFα, known to be cytotoxic towards beta-cells and believed to be implicated in decreased beta-cell function and mass in diabetic states. IL-13 was able to protect beta-cells from IL-1β induced death alone ([Figure 4](#fig4){ref-type="fig"}A) or in combination with IFNγ and TNFα ([Figure 4](#fig4){ref-type="fig"}B). However, IL-13 was unable to preserve beta-cell glucose stimulated insulin secretion impaired by 48 h treatment with IL-1β ([Figure 4](#fig4){ref-type="fig"}C).

We show here also that IL-1β induced alpha-cell death in primary rat non beta-cells (containing over 75% alpha-cells) after FACS sorting ([Figure 4](#fig4){ref-type="fig"}D). Interestingly, alpha-cells were also protected by IL-13 from IL-1β induced death.

IL-13 treatment prevents the impact of IL-1β on IRS2 protein expression ([Figure 4](#fig4){ref-type="fig"}E) and decreases NFκB p65 phosphorylation induced by IL-1β stimulation ([Figure 4](#fig4){ref-type="fig"}F). Moreover IL-13 exposure induces an increase of NFκB (p65) protein expression similar to what was observed for IRS2 ([Figure 4](#fig4){ref-type="fig"}G).

3.5. IL-13 counter-regulates IL-1β gene expression without affecting the nuclear translocation of NFκB {#sec3.5}
------------------------------------------------------------------------------------------------------

We next investigated whether the protective effects of IL-13 were perhaps mediated by NFκB. Rat primary beta-cells treated for 48 h with IL-13 in the presence or not of IL-1β were stained for NFκB (p65). The number of nuclei positive for NFκB was then carefully counted in order to quantify NFκB nuclear localization ([Figure 5](#fig5){ref-type="fig"}). IL-13 alone did not influence NFκB localization. Moreover, IL-13 did not counteract the nuclear re-localization of NFκB induced by IL-1β treatment ([Figure 5](#fig5){ref-type="fig"}), suggesting that IL-13 acts independently of this key transcription factor. This notwithstanding, and in an attempt to uncover genes possibly involved in the protective effects of IL-13 against IL-1β induced beta-cell death, we performed a transcriptome analysis of rat primary beta-cells treated for 48 h with IL-1β alone or in the presence of IL-13. Primary sorted rat beta-cells express the 2 receptor subunits IL-13Rα1 ([Figure 6](#fig6){ref-type="fig"}A) and IL-4Rα ([Figure 6](#fig6){ref-type="fig"}B) indispensible for a cellular IL-13 response. This confirms a recently published transcriptome analysis comparing human islets, a beta-cell fraction and a non beta-cell fraction showing that these 2 receptors are also expressed in human islets and beta-cells [@bib16]. In rat beta-cells, the expression of the 2 receptors was upregulated upon IL-1β treatment, suggesting that in the presence of a pro-inflammatory cytokine beta-cells are sensitized towards the anti-inflammatory actions of IL-13. As documented previously in beta-cells [@bib26], there was a tendency for IL-1β to upregulate its own expression ([Figure 6](#fig6){ref-type="fig"}C) even if this failed to achieve statistical significance in the present small series of experiments due to the low levels of expression of IL-1β in beta-cells and high degree of variability in the control situation. More importantly, IL-13 was able to downregulate such self-induction of IL-1β ([Figure 6](#fig6){ref-type="fig"}C).

Among the over 6000 genes affected by treatment of rat beta-cells with IL-1β, only 110 were significantly counter regulated by IL-13 ([Table 1](#tbl1){ref-type="table"}). The IL-13 counter regulation was entire (IL-1β + IL-13 condition back to control value) only for 19 among these 110 genes. Of these 110 genes, 63 were upregulated by IL-1β with total or partial abrogation of this increase by IL-13 and 47 genes were downregulated by IL-1β with total or partial abrogation of this decrease by IL-13 ([Table 1](#tbl1){ref-type="table"}). Of the 63 genes with increased expression upon IL-1β treatment and partial or full protection by IL-13, 9 were singled out as being of particular interest in the context of beta-cell apoptosis and dysfunction (grey lines in [Table 1](#tbl1){ref-type="table"}). These genes are implicated in inflammation (Csf3, Ccl20, IL-23), stress responses (Ern1, CYBB, Cat, IGFbp1), transcription (Myc) or insulin secretion (Slc1a2). Similarly, of the 47 genes downregulated by IL-1β with partial or full protection by IL-13, 6 were of particular interest in the context of our study (grey lines in [Table 1](#tbl1){ref-type="table"}). These genes are involved in insulin processing and secretion (Pcsk1, Slc30a8, Vsnl1) or encode secreted proteins (IGFbp3, Itnl1). Interestingly, Galnt14 is highly increased in cells treated with IL-13 and IL-1β compared to IL-1β alone.

4. Discussion {#sec4}
=============

It has recently been shown that IL-13 plays an important role in glucose homeostasis and that its level is decreased in the circulation of type 2 diabetic patients but increased in the adipose tissue of obese individuals [@bib6], [@bib10], [@bib11]. IL-13 regulates glucose homeostasis in the liver and plays a unique protective role by limiting adipose tissue inflammation [@bib6], [@bib10]. The impact that IL-13 could exert on beta-cells has so far been studied mainly on beta-cell lines [@bib7]. Our study shows for the first time, that IL-13 directly impacts primary rat and, more importantly, human beta-cells, acting to improve survival both under standard culture conditions and in the face of cytotoxic cytokines. We thus show that IL-13 decreases human beta-cell death, either in a pure population or in the presence of other islet cell types. These results, together with those obtained by transcriptome analysis of human purified beta-cells or islets [@bib16] where IL-13Rα1 and IL4Rα, the 2 receptor subunits indispensable for IL-13 signaling, were shown to be expressed at the mRNA level in beta-cells and in islets, may suggest that IL-13 directly interacts with beta-cells. Only one study has so far shown that IL-13 might impact human islet cell signaling pathways with the induction of STAT3 and STAT6 phosphorylation [@bib12].

We demonstrate that the decrease in basal death of rat beta-cells was associated with increased IRS2 protein expression and Akt phosphorylation. The IL-13 receptor subunit IL-4Rα has been shown previously to be able to interact with IRS2 [@bib7], and, in turn, this insulin receptor substrate is known to be essential in maintaining proper functional beta-cell mass [@bib27]. It was also associated with an increase in the spreading of beta-cells and in the protein expression associated with this process. These data are in line with a previous study on embryonic fibroblast demonstrating that focal adhesion remodeling is involved in cell survival [@bib24]. Moreover, the transcriptome analysis of rat beta-cells in the presence of IL-13 revealed that it is able to increase the expression of Cish. This protein forms part of a classical negative feedback system that regulates cytokine signal transduction and is involved in the negative regulation of cytokines that signal through the JAK-STAT5 pathway [@bib25]. Together our results thus show that IL-13 positively impacts beta-cell survival via the IRS2/Akt pathway and also by inhibiting cytokine signaling. Moreover, IL-13 through adhesion formation could protect cells from apoptosis by regulating the activation of NF-κB as demonstrated in fibroblasts [@bib24].

IL-13 is also able to protect beta-cells against a cocktail of cytokines (IL-1β, TNFα and IFNγ) thought to contribute to decreased beta-cell mass in both major types of diabetes. Moreover, as recently shown, IL-13 is decreased in patients with type 2 diabetes [@bib11]. The imbalance between pro- and anti-inflammatory cytokines has been suggested to be central in the beta-cell damage that occurs during progression towards clinically manifest type 2 diabetes. Our results showing the protective effect of IL-13 against cell death induced by pro-inflammatory cytokine are in perfect keeping with this hypothesis.

IL-13-induced IRS2 protein expression is not influenced by IL-1β treatment, suggesting that IRS2 is implicated in the mediation of the protective role played by IL-13 against IL-1β−induced apoptosis. IL-13 protection of beta-cells against IL-1β-induced death is independent of the translocation (and thus activation) of NFκB, but it prevents the decrease in NFκB phosphorylation and total protein expression induced by IL-1β treatment. However, this does not mean that the IL-13 effect is transcription independent since we could identify genes regulated by IL-1β and counter-regulated by IL-13. IL-13 impacts NFκB turnover by modifying its protein expression, without impacting its localization or mRNA expression. IL-1β impacts drastically the transcriptome of beta-cells; whereas IL-13 does not massively counter-regulate the perturbed expression of all these genes it may perhaps correct only the expression of those few genes that are important for beta-cell survival.

While it is hard to interpret the data without considering the combined effect of all the changes exerted by IL-13 in the face of IL-1β, some of the impacted genes do stand out as logical candidates that may contribute towards the protective effects of IL-13. Among them, some genes appear of particular interest including: Cybb which forms reactive oxygen species (ROS) and has been shown to be involved in beta-cell dysfunction in response to glycotoxic or pro-inflammatory cytokine response [@bib28], [@bib29]; Ern1 which is an important player of the endoplasmic reticulum (ER) stress and unfolded protein responses [@bib30]; Myc which has been shown to induce beta-cell dysfunction and apoptosis [@bib31]; Csf3 and Ccl20 that code for cytokines implicated in inflammation. By dampening the increased expression of the above-mentioned genes in response to IL-1β, IL-13 may improve beta-cell survival in the presence of cytotoxic cytokines.

Among the genes downregulated by IL-1β but not in the presence of IL-13, some are of particular interest in the context of beta-cell resistance to inflammatory stress. Cd83 is involved in antigen presentation and SNPs in this gene have been shown to be associated with type 1 diabetes [@bib25]. Thus, its upregulation by IL-13, also in the presence of IL-1β, might be part of a beta-cell survival process. Ltn1, also known as omentin-1, is a recently discovered adipokine that is reduced in type 2 diabetic patients [@bib32]. The impact of this adipokine on beta-cells remains to be studied; however, omentin-1 suppresses myocyte apoptosis in an ischemia model through Akt and AMPK activation [@bib33]. This suggests that this adipokine might play a role in the IL-13 protective effect against IL-1β, since IL-13 is able to restore its transcription level in IL-1β treated beta-cells.

In other tissues, Galnt14 has been shown to impact on IGFBP3 to decrease apoptosis [@bib34]. As well, an increase of a 2,6 sialyted carbohydrate produced by ST6galnac3 has been shown to render cells resistant to apoptosis [@bib35]. Therefore, the increase of Galnt14 and St6galnac3 expression upon IL-13 treatment could partly explain the decrease of baseline beta-cell apoptosis observed after IL-13 treatment.

Interestingly, IL-13 exerts its protective effect against IL-1β not only on beta-cells but also on alpha-cells. Although glucagon is the major secretory product of alpha-cells, acting to increase hepatic glucose production, alpha-cells can also produce GLP-1 under certain particular situations, allowing for a possible paracrine effect on beta-cells to enhance their glucose-stimulated insulin secretion and improve their survival [@bib36]. We thus speculate that under conditions of islet inflammation, when alpha-cell GLP-1 production is believed to be increased, preserving alpha-cells may actually be beneficial for preserving beta-cell functional mass, contrary to received thinking. Furthermore, it has been shown that under conditions of extreme beta-cell ablation in rodents, alpha-cells can be trans-differentiated into beta-cells [@bib37], raising the interesting hypothesis that in the clinical setting of type 2 diabetes, protecting alpha-cells against IL-1β may indirectly help preserve beta-cell mass.

5. Conclusions {#sec5}
==============

Our study is in line with previous studies showing a positive impact of IL-13 on transformed beta-cell lines (for review see [@bib7]). However, we show for the first time that IL-13 can directly affect human beta-cell survival. We show that IL-13 protects beta-cells from IL-1β induced apoptosis, a cytokine known to play an important role in type 2 diabetes. These positive effects are mediated via the IRS2/Akt pathway and the regulation of genes implicated in the cellular stress response. While the complete pathway underlying the IL-13 protective effects on beta-cell survival remains to be fully elucidated, our study indicates that IL-13 may be an important new player in helping beta-cells survive cytokine attack in both major forms of diabetes and may be a useful adjunct to existing or novel anti-proinflammatory cytokine therapy, acting not only on the liver and adipocytes as previously suggested by others [@bib6], [@bib10] but also on islets.
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![**IL-13 decreases human and rat beta-cell death**. Human islets, human or rat dispersed islets or sorted human or rat beta-cells were cultured for 48 h with IL-13 (10 ng/ml). A--C: Insulin secretion. A: Human islet insulin secretion: 2.8 mM glucose (open bars), 16.7 mM glucose (closed bars); n = 5. Rat dispersed islet cells (B; n = 5) or sorted beta-cells (C; n = 7) insulin secretion: 2.8 mM glucose (open bars), 16.7 mM glucose (closed bars). D: Rat beta-cell proliferation. BrdU-positive beta-cells in dispersed rat islet cells (normalized to control = 9.98 ± 1.93% BrdU-positive beta-cells); n = 5. E-H Beta-cell death. E: TUNEL-positive beta-cells among dispersed human islet cells (normalized to control = 0.47 ± 0.1% TUNEL-positive beta-cells); n = 5. F: TUNEL-positive sorted human beta-cells (normalized to control = 1.06 ± 0.32% TUNEL-positive beta-cells); n = 4. G: TUNEL-positive beta-cells in dispersed rat islet cells (normalized to control = 0.12 ± 0.03% TUNEL-positive beta-cells); n = 3. H: TUNEL-positive sorted rat beta-cells (normalized to control = 0.06 ± 0.02% TUNEL-positive beta-cells); n = 5. \*p \< 0.05 *vs*. control as tested by Student\'s t-test.](gr1){#fig1}

![**IL-13 induces Akt phosphorylation, increases IRS2 protein expression and induces actin and focal adhesion remodeling in primary sorted rat beta-cells**. Rat sorted beta-cells were cultured with IL-13 (10 ng/ml) for the indicated times. Phosphorylation and total protein levels were quantified by western blot. A: Akt serine-473 phosphorylation after 10--60 min exposure to IL-13; B: Akt serine-473 phosphorylation after 48 h exposure to IL-13; C: Akt1 total protein after 48 h exposure to IL-13; D: Akt2 total protein after 48 h exposure to IL-13. E. IRS2 total protein after 48 h exposure to IL-13. n = 4. F: Primary β-cell cells were cultured in complete medium for 48 h ± IL-13 (10 ng/ml). Cells were subsequently fixed and stained for actin (with phalloidin, purple), pY397FAK (green) and PAX (red). All images are fully representative of three independent experiments. \*p \< 0.05 *vs*. control as tested by ANOVA followed by Bonferroni post hoc test (A) or Student\'s t-test (E).](gr2){#fig2}

![**IL-13 increases expression of 4 beta-cell genes**. Sorted rat primary beta-cells were cultured for 48 h ± IL-13 (10 ng/ml) and their transcriptome profiled by RNAseq. A: Cish; B: Cd83; C: Galnt14; D: St6galnac3. Data for respective levels of mRNA are presented as reads per kilobase per million mapped reads (RPKM), n = 3. \*p \< 0.05 *vs*. control, dseq2 adjusted p value.](gr3){#fig3}

![**Protection by IL-13 against cytokine-induced islet cell death**. A--G: Sorted rat primary beta-cells or alpha-cells were treated for 48 h with IL-13 (10 ng/ml) ± IL-1β (20 ng/ml) or cytomix (IL-1β + TNFα + INFγ, each 20 ng/ml). A: TUNEL-positive rat sorted beta-cells; n = 3. B: TUNEL-positive rat sorted beta-cells; n = 3. C: Rat beta-cell insulin secretion: open bars 2.8 mM glucose; closed bars 16.7 mM glucose; n = 4. D: TUNEL-positive alpha-cells in a population of sorted rat islet non-beta cells; n = 3. E--G: Phosphorylation and total protein expression were quantified by western blot. E: IRS2 total protein expression (n = 4). F: NFkB p65 phosphorylation (n = 4). G: NFkB total protein expression (n = 4). \*p \< 0.05 as tested by ANOVA followed by Bonferroni post hoc test.](gr4){#fig4}

![**IL-13 does not influence IL-1β induced NFκB nuclear relocalization**. Primary rat sorted beta-cells were cultured for 48 h with IL-1β (20 ng/ml) ± IL-13 (10 ng/ml). A: Representative images showing NFκB (red) localization. B: Beta-cells with nuclear localization of NFκB (n = 6). \*p \< 0.05 as tested by ANOVA followed by Bonferroni post hoc test.](gr5){#fig5}

![**IL-13 receptor subunit and IL-1β expression in beta-cells**. Sorted rat primary beta-cells were cultured for 48 h with IL-1β (20 ng/ml) ± IL-13 (10 ng/ml) and transcriptomes profiled by RNAseq. A: IL-13Rα1; B: IL-4Rα; C: IL-1β. Data are presented as reads per kilobase per million mapped reads (RPKM), n = 3. \*p \< 0.05 *vs*. control, dseq2 adjusted p value.](gr6){#fig6}

###### 

**IL-13 counterregulates the expression of genes regulated by IL-1β**. Sorted rat primary beta-cells were cultured for 48 h with IL-1β (20 ng/ml) ± IL-13 (10 ng/ml) and transcriptomes profiled by RNAseq. Data are presented as fold-changes between control and IL-1β and between IL-1β and IL-1β + IL-13 conditions, n = 3.

  Gene name    Gene ID              Control versus IL1β   IL1β versus IL1β + IL13           
  ------------ -------------------- --------------------- ------------------------- ------- ----------
  Slc1a2       ENSRNOG00000005479   6.06                  7.61E-17                  0.86    4.51E-02
  Myc          ENSRNOG00000004500   24.42                 1.79E-46                  0.82    4.49E-02
  SRXN1        ENSRNOG00000031167   3.27                  2.48E-29                  0.78    4.49E-02
  Aldoa        ENSRNOG00000023647   2.07                  6.01E-59                  0.90    4.32E-02
  Fhl2         ENSRNOG00000016866   23.43                 1.26E-81                  0.77    4.30E-02
  Lcn2         ENSRNOG00000013973   372.22                0.00E+00                  0.90    4.25E-02
  Dvl1         ENSRNOG00000019423   1.33                  1.47E-05                  0.83    3.61E-02
  Kcnn3        ENSRNOG00000020706   3.94                  1.59E-10                  0.82    3.40E-02
  Saal1        ENSRNOG00000011895   3.92                  1.35E-20                  0.72    3.00E-02
  Hnrnpa0      ENSRNOG00000039876   1.24                  1.91E-02                  0.80    2.93E-02
  Adm          ENSRNOG00000027030   15.35                 1.01E-133                 0.79    2.82E-02
                                                                                            
  Il23a        ENSRNOG00000003254   10.41                 1.35E-62                  0.72    2.46E-02
  Ern1         ENSRNOG00000012864   2.07                  6.36E-31                  0.87    2.39E-02
  Pfkfb3       ENSRNOG00000018911   18.00                 1.19E-132                 0.79    2.31E-02
  Pfkl         ENSRNOG00000001214   1.84                  1.93E-19                  0.85    2.16E-02
  Fblim1       ENSRNOG00000011774   2.16                  4.98E-12                  0.73    2.11E-02
  Ddit4        ENSRNOG00000000577   1.93                  6.60E-12                  0.78    1.84E-02
                                                                                            
  Ccl20        ENSRNOG00000015992   67.65                 2.44E-27                  0.59    1.64E-02
  Sesn2        ENSRNOG00000042785   1.23                  1.15E-04                  0.87    1.58E-02
  Raph1        ENSRNOG00000014722   2.04                  3.18E-15                  0.80    1.51E-02
                                                                                            
  Cybb         ENSRNOG00000003622   86.22                 3.70E-98                  0.77    1.22E-02
  Sqstm1       ENSRNOG00000003147   2.75                  5.13E-100                 0.88    1.08E-02
  Stc2         ENSRNOG00000020729   21.11                 3.27E-09                  0.77    9.37E-03
  Ugdh         ENSRNOG00000002643   4.89                  2.13E-170                 0.86    9.13E-03
  Ugt1a8       ENSRNOG00000018740   3.81                  8.36E-125                 0.87    9.13E-03
  Fhdc1        ENSRNOG00000024594   1.58                  5.21E-14                  0.81    8.71E-03
  Rusc2        ENSRNOG00000045843   2.03                  1.15E-13                  0.77    8.71E-03
  Tle3         ENSRNOG00000013013   1.37                  2.63E-07                  0.86    8.25E-03
  Gtpbp2       ENSRNOG00000019332   3.12                  8.63E-79                  0.83    5.43E-03
  NA           ENSRNOG00000007930   2.23                  4.75E-20                  0.77    5.40E-03
  Nqo1         ENSRNOG00000012772   3.34                  2.86E-117                 0.86    4.29E-03
  Slc16a1      ENSRNOG00000019996   22.94                 7.13E-87                  0.73    4.19E-03
  RGD1310819   ENSRNOG00000018366   4.20                  2.53E-65                  0.80    3.79E-03
  Ppp1r15a     ENSRNOG00000020938   5.74                  6.26E-223                 0.83    3.67E-03
  Ets2         ENSRNOG00000001647   1.78                  6.49E-24                  0.86    3.47E-03
  Fndc3b       ENSRNOG00000024089   1.35                  4.00E-07                  0.84    3.40E-03
                                                                                            
  Csf3         ENSRNOG00000008525   182.28                1.84E-20                  0.48    3.09E-03
  Abcc3        ENSRNOG00000002948   1.49                  7.99E-10                  0.83    2.91E-03
  Ldlr         ENSRNOG00000009946   1.36                  7.46E-07                  0.84    2.85E-03
  Dgat2        ENSRNOG00000016573   16.34                 2.89E-117                 0.75    1.95E-03
  Jund         ENSRNOG00000019568   2.45                  7.44E-20                  0.78    1.89E-03
  Arnt2        ENSRNOG00000013017   1.89                  1.49E-31                  0.84    1.73E-03
  Nceh1        ENSRNOG00000013313   3.39                  1.07E-76                  0.83    7.64E-04
                                                                                            
  Cat          ENSRNOG00000008364   2.35                  3.29E-38                  0.85    5.95E-04
  Ak4          ENSRNOG00000045738   28.25                 1.84E-95                  0.68    1.16E-04
  Gys1         ENSRNOG00000020812   3.81                  1.68E-76                  0.78    1.08E-04
  Slc2a1       ENSRNOG00000007284   11.24                 0.00E+00                  0.80    9.99E-05
  Gstp1        ENSRNOG00000018237   9.99                  2.00E-174                 0.81    8.15E-05
  Bhlhe40      ENSRNOG00000007152   4.35                  5.08E-65                  0.76    8.01E-05
  Elmsan1      ENSRNOG00000010653   5.03                  1.36E-109                 0.80    6.17E-05
  Pnpla7       ENSRNOG00000008190   3.20                  4.35E-36                  0.71    5.79E-05
  Pcsk6        ENSRNOG00000011526   34.78                 4.38E-30                  0.84    5.21E-05
  Ptgs1        ENSRNOG00000007415   9.58                  4.15E-40                  0.60    2.16E-05
  NA           ENSRNOG00000021752   2.58                  1.49E-14                  0.59    2.16E-05
  Lrp11        ENSRNOG00000014303   1.96                  1.55E-38                  0.85    8.61E-06
                                                                                            
  Igfbp1       ENSRNOG00000008371   4.50                  2.88E-14                  0.44    5.05E-06
  Vegfa        ENSRNOG00000019598   1.95                  1.09E-53                  0.82    8.88E-07
  Gdf15        ENSRNOG00000019661   13.83                 3.20E-77                  0.73    5.66E-08
  Mmp13        ENSRNOG00000008478   45.57                 3.40E-86                  0.54    3.26E-10
  Orm1         ENSRNOG00000007886   218.28                1.06E-34                  0.55    2.90E-12
  Fabp5        ENSRNOG00000049075   39.12                 9.32E-84                  0.71    2.69E-12
  Akr1b8       ENSRNOG00000009734   89.26                 9.74E-47                  0.63    9.94E-17
  Slc7a11      ENSRNOG00000010210   17.51                 1.37E-71                  0.71    9.70E-18
                                                                                            
  Slc30a8      ENSRNOG00000004747   0.13                  9.42E-247                 1.21    9.52E-04
  Slc38a5      ENSRNOG00000027767   0.15                  5.68E-206                 1.24    1.50E-05
  Gnas         ENSRNOG00000047374   0.32                  3.87E-155                 1.18    3.22E-05
  Myh10        ENSRNOG00000002886   0.31                  1.36E-142                 1.26    1.86E-06
                                                                                            
  Pcsk1        ENSRNOG00000011107   0.29                  8.41E-126                 1.34    7.44E-09
  Gm20721      ENSRNOG00000048879   0.33                  3.22E-125                 1.15    1.58E-02
                                                                                            
  Galnt14      ENSRNOG00000007951   0.14                  2.59E-114                 4.03    7.05E-61
  Lbh          ENSRNOG00000039902   0.22                  1.38E-102                 1.25    1.58E-02
  Pam          ENSRNOG00000033280   0.35                  1.57E-81                  1.14    1.81E-03
  Maob         ENSRNOG00000029778   0.35                  3.17E-80                  1.47    1.82E-14
  Pgm5         ENSRNOG00000015406   0.37                  2.42E-70                  1.33    3.23E-06
                                                                                            
  Vsnl1        ENSRNOG00000005345   0.20                  5.26E-66                  1.46    4.25E-03
  Sphkap       ENSRNOG00000016388   0.53                  1.72E-33                  1.30    9.26E-11
  Cd83         ENSRNOG00000018092   0.27                  7.78E-31                  1.79    2.36E-04
  Matn2        ENSRNOG00000006060   0.29                  7.38E-30                  1.87    1.98E-08
  AW551984     ENSRNOG00000005960   0.52                  1.62E-28                  1.61    1.59E-21
  Aass         ENSRNOG00000039494   0.42                  2.85E-26                  1.52    6.93E-12
  Scg2         ENSRNOG00000015055   0.64                  3.44E-26                  1.12    1.84E-02
  Ggh          ENSRNOG00000007351   0.52                  1.00E-23                  1.28    3.71E-04
  Tspan7       ENSRNOG00000003229   0.65                  6.49E-21                  1.15    9.83E-03
  Scfd1        ENSRNOG00000031203   0.59                  1.17E-20                  1.16    4.60E-02
  Crp          ENSRNOG00000000053   0.44                  2.20E-18                  2.14    2.15E-22
  Atp6v1a      ENSRNOG00000001992   0.66                  3.37E-16                  1.16    1.21E-02
  Dnah9        ENSRNOG00000004171   0.22                  6.24E-16                  3.12    5.64E-08
  Rtn4rl1      ENSRNOG00000003121   0.54                  1.10E-14                  1.69    4.58E-13
  Lrrtm4       ENSRNOG00000021938   0.26                  3.70E-13                  2.11    3.03E-03
  NA           ENSRNOG00000021687   0.09                  6.44E-12                  14.32   1.49E-19
  Gc           ENSRNOG00000003119   0.72                  6.60E-11                  1.16    2.55E-03
  Gad1         ENSRNOG00000000007   0.65                  9.84E-11                  1.24    8.71E-07
  Camk2n1      ENSRNOG00000016322   0.63                  3.82E-10                  1.18    3.50E-02
  Trh          ENSRNOG00000011824   0.70                  1.21E-09                  1.15    4.35E-02
  Galr1        ENSRNOG00000016654   0.25                  1.94E-09                  2.75    4.05E-04
  Cox7b        ENSRNOG00000028451   0.64                  1.01E-08                  1.25    1.84E-02
  Sema5a       ENSRNOG00000011977   0.66                  1.24E-07                  1.35    1.09E-04
  Fam92a1      ENSRNOG00000016338   0.68                  5.32E-07                  1.28    1.84E-02
  Hgfac        ENSRNOG00000009572   0.58                  7.49E-07                  1.42    2.76E-02
  Hrsp12       ENSRNOG00000005437   0.68                  4.03E-06                  1.37    1.90E-04
  Marcks       ENSRNOG00000000579   0.65                  4.70E-06                  1.38    8.20E-04
  Col6a3       ENSRNOG00000019648   0.23                  6.77E-05                  3.01    3.68E-02
  Atp1b1       ENSRNOG00000002934   0.84                  5.49E-04                  1.14    3.09E-03
  Bche         ENSRNOG00000009826   0.59                  1.07E-03                  1.96    9.84E-06
                                                                                            
  Igfbp3       ENSRNOG00000008645   0.48                  1.85E-03                  2.06    1.14E-02
  Accsl        ENSRNOG00000042533   0.23                  1.83E-02                  4.79    6.49E-03
  Tsc22d3      ENSRNOG00000013786   0.81                  1.84E-02                  1.52    1.50E-05
  Il1r1        ENSRNOG00000014504   0.89                  2.10E-02                  1.57    1.17E-42
                                                                                            
  Itln1        ENSRNOG00000004678   0.78                  2.39E-02                  1.34    2.17E-02
  Tmprss2      ENSRNOG00000001976   0.79                  3.14E-02                  1.51    2.75E-08

[^1]: Present address: Sabine Rütti, Department of Physiology, University of Lausanne, Rue du Bugnon 7, 1005 Lausanne, Switzerland.
